Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 348-357

  Verreault, M ^a   Wehbe, M ^b,c   Strutt, D ^b   Masin, D ^b   Anantha, M ^b   Walker, D ^d   Chu, F ^d   Backstrom, I ^b   Kalra, J ^b   Waterhouse, D ^b   Yapp, D T ^b,c   Bally, M B ^b,c,e  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

^e Center for Drug Research and Development   (Canada)

Author keywords

Cancer; Drug delivery; Glioblastoma; Irinotecan; Liposomes; Tumor associated vasculature

Indexed keywords

ANIMALS; BLOOD VESSELS; CELL CULTURE; DRUG DELIVERY; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; LIPOSOMES; TRANSMISSION ELECTRON MICROSCOPY;

CANCER; DIFFERENT TREATMENTS; DNA METHYLTRANSFERASES; GLIOBLASTOMAS; IRINOTECAN; SEQUENTIAL TREATMENTS; VASCULAR NORMALIZATION; VASCULATURE;

TUMORS;

ANTINEOPLASTIC AGENT; IRINOPHORE C; IRINOTECAN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; CAMPTOTHECIN; DACARBAZINE; LIPOSOME; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; EFFECTIVE DOSE (PHARMACOLOGY); GLIOBLASTOMA; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG FORMULATION; DRUG SCREENING; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TIME FACTOR; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CAMPTOTHECIN; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMPOUNDING; GLIOBLASTOMA; HUMANS; LIPOSOMES; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946552764     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.10.053     Document Type: Article

References (56)

1. E.C. Holland Glioblastoma multiforme: the terminator Proc. Natl. Acad. Sci. U. S. A. 97 12 2000 6242 6244
2. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J.B. Taphoorn, R.C. Janzer, and et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 5 2009 459 466
3. P. Vajkoczy, and M.D. Menger Vascular microenvironment in gliomas J. Neuro-Oncol. 50 1-2 2000 99 108
4. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, and et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 10 2005 987 996
5. I. Bosma, M.J. Vos, J.J. Heimans, M.J. Taphoorn, N.K. Aaronson, T.J. Postma, and et al. The course of neurocognitive functioning in high-grade glioma patients Neuro-Oncology 9 1 2007 53 62
6. S. Kesari Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments Semin. Oncol. 38 6 2011 S2 S10
7. W. Stummer, H.J. Reulen, T. Meinel, U. Pichlmeier, W. Schumacher, J.C. Tonn, and et al. Extent of resection and survival on glioblastoma multiforme-identification of and adjustment for bias Neurosurgery 62 3 2008 564 574
8. J. Portnow, B. Badie, M. Chen, A. Liu, S. Blanchard, and T.W. Synold The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation Clin. Cancer Res. 15 22 2009 7092 7098
9. L.P. Serwer, and C.D. James Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations Adv. Drug Deliv. Rev. 64 7 2012 590 597
10. P. Vajkoczy, and M.D. Menger Vascular microenvironment in gliomas Cancer Treat. Res. 117 2004 249 262
11. P. Vajkoczy, L. Schilling, A. Ullrich, P. Schmiedek, and M.D. Menger Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse J. Cereb. Blood Flow Metab. 18 5 1998 510 520
12. R.G. Blasberg, T. Kobayashi, M. Horowitz, J.M. Rice, D. Groothuis, P. Molnar, and et al. Regional blood-to-tissue transport in ethylnitrosourea-induced brain tumors Ann. Neurol. 14 2 1983 202 215
13. W.M. Pardridge Blood-brain barrier delivery Drug Discov. Today 12 1-2 2007 54 61
14. D.R. Groothuis, J.M. Fischer, J.F. Pasternak, R.G. Blasberg, N.A. Vick, and D.D. Bigner Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas Cancer Res. 43 7 1983 3368 3373
15. J.M. Liu, B.Y. Mao, S. Hong, Y.H. Liu, and X.J. Wang The postoperative brain tumour stem cell (BTSC) niche and cancer recurrence Adv. Ther. 25 5 2008 389 398
16. G. Frosina DNA repair and resistance of gliomas to chemotherapy and radiotherapy Mol. Cancer Res. 7 7 2009 989 999
17. C. Lu, and A. Shervington Chemoresistance in gliomas Mol. Cell. Biochem. 312 1-2 2008 71 80
18. M. Sanchez-Martin Brain tumour stem cells: implications for cancer therapy and regenerative medicine Curr. Stem Cell Res. Ther. 3 3 2008 197 207
19. R.K. Jain Normalizing the tumor microenvironment to treat cancer: bench to bedside to biomarkers Angiogenesis 17 3 2014 721
20. M. Leunig, F. Yuan, M.D. Menger, Y. Boucher, A.E. Goetz, K. Messmer, and et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma Ls174t in SCID mice Cancer Res. 52 23 1992 6553 6560
21. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, and et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer New Engl. J. Med. 350 23 2004 2335 2342
22. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, and et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer New Engl. J. Med. 355 24 2006 2542 2550
23. F. Baffert, T. Le, B. Sennino, G. Thurston, C.J. Kuo, D. Hu-Lowe, and et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am. J. Physiol. Heart Circ. Physiol. 290 2 2006 H547 H559
24. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat. Med. 7 9 2001 987 989
25. E. Ramsay, J. Alnajim, M. Anantha, J. Zastre, H. Yan, M. Webb, and et al. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur. J. Pharm. Biopharm. 68 3 2008 607 617
26. E.C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, D. Strutt, and et al. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors Clin. Cancer Res. 14 4 2008 1208 1217
27. R. Neijzen, M.Q. Wong, N. Gill, H. Wang, T. Karim, M. Anantha, and et al. Irinophore C, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer J. Control. Release: Off. J. Control. Release Soc. 199 2015 72 83
28. J.H. Baker, J. Lam, A.H. Kyle, J. Sy, T. Oliver, S.J. Co, and et al. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin Clin. Cancer Res. 14 22 2008 7260 7271
29. M. Verreault, D. Strutt, D. Masin, M. Anantha, D. Waterhouse, D.T. Yapp, and et al. Irinophore C, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model J. Control. Release: Off. J. Control. Release Soc. 158 1 2011 34 43
30. M. Verreault, D. Strutt, D. Masin, M. Anantha, A. Yung, P. Kozlowski, and et al. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (irinophore C), doxorubicin (caelyx(R)) or vincristine BMC Cancer 11 2011 124
31. M. Verreault, D. Strutt, D. Masin, D. Fink, R. Gill, and M.B. Bally Development of glioblastoma cell lines expressing red fluorescence for non-invasive live imaging of intracranial tumors Anticancer Res. 31 6 2011 2161 2171
32. M. Verreault, D. Strutt, D. Masin, M. Anantha, A. Yung, P. Kozlowski, and et al. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore CTM), doxorubicin (Caelyx®) or vincristine BMC Cancer 11 2011;Apr 8 124 142
33. S. Fritzell, E. Sanden, S. Eberstal, E. Visse, A. Darabi, and P. Siesjo Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion Cancer Immunol. Immunother. CII. 62 9 2013 1463 1474
34. L.D. Mayer, M.J. Hope, and P.R. Cullis Vesicles of variable sizes produced by a rapid extrusion procedure Biochim. Biophys. Acta 858 1 1986 161 168
35. D. Shcherbo, C.S. Murphy, G.V. Ermakova, E.A. Solovieva, T.V. Chepurnykh, A.S. Shcheglov, and et al. Far-red fluorescent tags for protein imaging in living tissues Biochem. J. 418 3 2009 567 574
36. W.S. Kamoun, C.D. Ley, C.T. Farrar, A.M. Duyverman, J. Lahdenranta, D.A. Lacorre, and et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J. Clin. Oncol. 27 15 2009 2542 2552
37. F. Winkler, S.V. Kozin, R.T. Tong, S.S. Chae, M.F. Booth, I. Garkavtsev, and et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 6 2004 553 563
38. P. Baluk, H. Hashizume, and D.M. McDonald Cellular abnormalities of blood vessels as targets in cancer Curr. Opin. Genet. Dev. 15 1 2005 102 111
39. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 5706 2005 58 62
40. S.D. Baker, M. Wirth, P. Statkevich, P. Reidenberg, K. Alton, S.E. Sartorius, and et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer Clin. Cancer Res. 5 2 1999 309 317
41. F. Marchesia, M. Turriziani, G. Tortorelli, G. Avvisati, F. Torino, and L. De Vecchis Triazene compounds: mechanism of action and related DNA repair systems Pharmacol. Res. 56 4 2007 275 287
42. M.E. Hegi, L. Liu, J.G. Herman, R. Stupp, W. Wick, M. Weller, and et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity J. Clin. Oncol. Off. J. Soc. Clin. Oncol. 26 25 2008 4189 4199
43. R.K. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers J. Clin. Oncol. 31 17 2013 2205 2218
44. D.R. Groothuis, J.F. Pasternak, J.M. Fischer, R.G. Blasberg, D.D. Bigner, and N.A. Vick Regional measurements of blood flow in experimental RG-2 rat gliomas Cancer Res. 43 7 1983 3362 3367
45. F. Yuan, H.A. Salehi, Y. Boucher, U.S. Vasthare, R.F. Tuma, and R.K. Jain Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows Cancer Res. 54 17 1994 4564 4568
46. J.W. Baish, Y. Gazit, D.A. Berk, M. Nozue, L.T. Baxter, and R.K. Jain Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model Microvasc. Res. 51 3 1996 327 346
47. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, and R.K. Jain Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 64 11 2004 3731 3736
48. B.R. Deane, J. Greenwood, P.L. Lantos, and O.E. Pratt The vasculature of experimental brain tumours. Part 4. The quantification of vascular permeability J. Neurol. Sci. 65 1 1984 59 68
49. C.G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, C. Koike, and et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res. 60 19 2000 5565 5570
50. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, R.T. Tong, and et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 2 2004 145 147
51. Q. Zhou, and J.M. Gallo Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model Neuro-Oncology 11 3 2009 301 310
52. S. Ken, A. Deviers, T. Filleron, I. Catalaa, J.A. Lotterie, J. Khalifa, and et al. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination J. Neuro-Oncol. 124 3 2015 465 473
53. T.T. Batchelor, D.G. Duda, E. di Tomaso, M. Ancukiewicz, S.R. Plotkin, E. Gerstner, and et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J. Clin. Oncol. 28 17 2010 2817 2823
54. D.A. Reardon, A. Desjardins, K.B. Peters, S. Gururangan, J.H. Sampson, R.E. McLendon, and et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma J. Neuro-Oncol. 107 1 2012 155 164
55. A.G. Sorensen, T.T. Batchelor, W.T. Zhang, P.J. Chen, P. Yeo, M. Wang, and et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res. 69 13 2009 5296 5300
56. A.H. Ko, M.A. Tempero, Y.S. Shan, W.C. Su, Y.L. Lin, E. Dito, and et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer Br. J. Cancer 109 4 2013 920 925